Dr Reddy’s Share Price Reaches Fresh 52-Week High
Dr Reddy’s Laboratories continued its upward momentum during Monday’s trading session.
The company’s shares advanced by more than 4%, touching a fresh 52-week high of ₹1,410 on the National Stock Exchange.
The stock also moved close to its all-time high of ₹1,413, which was recorded in August 2024.
The latest rally marked the sixth consecutive session of gains for the pharmaceutical major.
During this six-session rally, the stock has appreciated by more than 11%, reflecting sustained buying activity.
Strong Momentum Ahead of Quarterly Earnings
Investor attention remains focused on the company’s upcoming financial results.
Dr Reddy’s Laboratories is scheduled to announce its financial performance for the quarter ended June 30, 2026, on July 22, 2026.
During the scheduled board meeting, the company will consider and approve both its standalone and consolidated unaudited financial statements for the first quarter of FY27.
Quarterly earnings announcements remain important corporate events as they provide updates on revenue, profitability, operational performance, and business developments.
Final Dividend Record Date Announced
The company has also announced its final dividend for shareholders.
Dr Reddy’s has declared a final dividend of ₹8 per equity share.
Shareholders whose names appear in the company’s records on the record date of July 10, 2026, will be eligible to receive the dividend, subject to the applicable corporate approval process.
Dividend declarations represent one of the regular methods through which companies distribute a portion of their profits to eligible shareholders.
USFDA Inspection Completed at Hyderabad Facility
Recently, the company completed an important regulatory inspection of one of its manufacturing facilities.
The United States Food and Drug Administration (USFDA) conducted a Pre-License Inspection (PLI) at Dr Reddy’s biologics manufacturing facility located in Bachupally, Hyderabad.
The inspection took place between June 16 and June 25, 2026.
Following completion of the inspection, the regulator issued a Form 483 containing seven observations.
According to the company, these observations will be addressed within the prescribed timeline provided by the regulatory authority.
The inspection forms part of the ongoing regulatory review process for pharmaceutical manufacturing facilities and follows earlier inspections conducted in 2023 and 2025.
Expansion of Oncology Portfolio in the United States
Dr Reddy’s has also strengthened its pharmaceutical offerings in the US market.
Earlier during the month, the company launched Bosutinib Tablets 400 mg, the first generic version of Bosulif available in the United States.
The product has been introduced through a collaboration with MSN Laboratories Private Limited.
Under the agreement:
- MSN Laboratories is responsible for product development and manufacturing.
- Dr Reddy’s holds the exclusive marketing rights for the product in the United States.
The launch further expands the company’s oncology product portfolio in one of its key international markets.
Significant Market Opportunity
The newly launched generic medicine enters an established therapeutic market.
According to industry sales data, the branded version of Bosulif 400 mg generated approximately US$253.8 million in sales during the twelve-month period ending April 2026.
The availability of the first generic version represents an important addition to Dr Reddy’s US product portfolio.
The US market continues to remain a significant revenue contributor for many Indian pharmaceutical manufacturers through both generic medicines and specialty products.
Pharmaceutical Business Continues Global Expansion
Dr Reddy’s Laboratories maintains a diversified presence across multiple international markets.
Its product portfolio covers various therapeutic categories, including oncology, cardiovascular care, gastroenterology, dermatology, respiratory medicines, and biologics.
The company continues to invest in manufacturing capabilities, product development, regulatory approvals, and international market expansion as part of its long-term business operations.
Conclusion
Dr Reddy’s Laboratories registered a fresh 52-week high after its share price gained more than 4%, extending its winning streak to six consecutive trading sessions. The stock remains in focus ahead of the company’s first-quarter FY27 financial results and the upcoming ₹8 per share final dividend. Meanwhile, the completion of the USFDA inspection at its Hyderabad biologics facility and the launch of the first generic Bosutinib tablets in the United States represent notable operational developments for the pharmaceutical company during the quarter.
Summary
Dr Reddy’s Laboratories witnessed strong buying interest on June 29, 2026, with its share price rising more than 4% to register a fresh 52-week high. The stock extended its winning streak for the sixth consecutive trading session and approached its lifetime high recorded in 2024. The rally comes ahead of the company’s first-quarter FY27 financial results and its upcoming final dividend. Recently, the company also completed a USFDA inspection at its Hyderabad biologics manufacturing facility and expanded its presence in the US pharmaceutical market through the launch of the generic version of Bosutinib tablets.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.
